In a recent interview on Stockhead TV’s Long Shortz, Dr. Camile Farah, CEO and Managing Director of Optiscan (ASX: OIL), shared details of a new partnership with Long Grove Pharmaceuticals aimed at transforming cancer detection.

The collaboration combines Optiscan’s real-time digital imaging technology with Long Grove’s FDA-approved contrast agent, fluorescein sodium (AK-FLUOR®), to enable intraoperative tissue assessment without the need for lab processing. Together, the companies are targeting FDA approval for new device-drug combinations, with breast surgery identified as the first clinical application.

This partnership marks a key milestone in Optiscan’s strategy to expand its clinical footprint and accelerate access to real-time digital pathology.

Watch the full interview on Stockhead here.

Watch the full interview on The Australian here.